Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 256

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 256
---
    166

    $
    (1,303,824
    )
     
    $
    (224
    )
     
    $
    202,485

The accompanying notes are an integral part of these consolidated financial statements.

 94

Adaptive Biotechnologies Corporation

Consolidated Statements of Cash Flows

(in thousands)

    Year Ended December 31,

    2024

    2023

    2022

    Operating activities

    Net loss
     
    $
    (159,595
    )
     
    $
    (225,304
    )
     
    $
    (200,368
    )

    Adjustments to reconcile net loss to net cash used in operating activities

    Depreciation expense

    17,553

    20,532

    19,221

    Noncash lease expense

    5,277

    6,920

    7,227

    Share-based compensation expense

    53,610

    62,908

    55,477

    Intangible assets amortization

    1,703

    1,699

    1,699

    Investment amortization

    (8,208
    )

    (9,184
    )

    741

    Impairment of long-lived assets

    7,205

    25,429

    —

    Inventory reserve

    1,938

    1,387

    2,638

    Noncash interest expense

    2,618

    5,300

    985

    Other

    141

    172

    (19
    )

    Changes in operating assets and liabilities

    Accounts receivable, net

    (3,744
    )

    2,032

    (22,648
    )

    Inventory

    5,372

    (2,838
    )

    817

    Prepaid expenses and other current assets

    83

    (1,930
    )

    3,551

    Accounts payable and accrued liabilities

    671

    (5,407
    )

    7,111

    Operating lease right-of-use assets and liabilities

    (9,385
    )

    (8,676
    )

    (4,050
    )

    Deferred revenue

    (10,478